

This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, is available on [our website](#) and various professional platforms.

On **November 30, 2018**, SanBio Co., Ltd. announced the conclusion of a committed credit line agreement and summary of procurement of funds in FY01/19.

Conclusion of committed credit line agreement

SanBio concluded a committed credit line agreement with MUFG Bank, Ltd. as of November 30, 2018 to procure funds for establishing manufacturing, logistics, and sales systems following the launch of SB623. Under this agreement the company is able to borrow up to JPY2.0bn in necessary funds in the period from November 30, 2018 to November 29, 2021. The agreement stipulates a 0.10% commitment fee (annual rate), and repayment will be made in full on the repayment date of each loan.

Overview of funds procured in FY01/19

Contracting party		Amount (JPYmn)	Effective date (Date approved)	Fund usage
MUFG Bank, Ltd.	Committed credit line	2,000	November 2018	• Establishment of manufacturing, logistics, and sales systems following launch of SB623
Sumitomo Mitsui Banking Corporation	Committed credit line	1,000	November 2018	• Establishment of manufacturing, logistics, and sales systems following launch of SB623
	Equity financing Share acquisition rights with provisions for exercise price revision through third-party allotment	11,000		• Establishment of manufacturing, logistics, and sales systems following launch of SB623 • Development of programs targeting chronic motor deficit from ischemic strokes in Japan and R&D aimed at regional expansion for future sales of SB623
Total		14,000		

This note is the most recent addition to the [full report](#).

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at <http://www.sharedresearch.jp>.

Disclaimer

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by the use of this report.

The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer

The report has been prepared by Shared Research under a contract with the company described in this report ("the company"). Opinions and views presented are ours where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include an opinion by us that could influence investment decisions in the company, such opinion may be in exchange for consideration or promise of consideration from the company to Shared Research.

Contact Details

Shared Research Inc.

3-31-12 Sendagi Bunkyo-ku Tokyo, Japan

<https://sharedresearch.jp>

Phone: +81 (0)3 5834-8787

Email: info@sharedresearch.jp